A combination of three drugs
Has become a hope for breast cancer patients with metastases to achieve a treatment response rate above 70% and progression-free survival of tumors over 14 months.
Miguel Martin, Chief of Medical Oncology, Hospital Gregorio Maranon de Madrid, and president of the Spanish Group for Breast Cancer Research (GEICAM) coordinated an international Phase II study that demonstrates the research, it has been presented at the meeting of the American Society of Clinical Oncology (ASCO).
While the preclinical phase had shown that the three drugs working together are getting more results than when acting separately.
The doctor said the results are positive and that this has been achieved “excellent good tolerability“.
The research, which involved ten Spanish hospitals, enrolled a total of 88 patients with advanced breast cancer, in order to determine the efficiency and safety of triple therapy.
The inquiry, in which 196 patients participated and 13 Spanish hospitals, comparing capecitabine intermittently, the standard way-or continuous-a new way-in women with this disease in the metastatic phase. The study aimed to demonstrate that continuous therapy, compared to the standard two weeks of treatment and rest, would apply a similar dose with less toxicity while maintaining efficiency.
For additional information visit the American Society of Clinical Oncology